Showing 1 to 8 of 8 Clinical Trials
CLINICAL TRIAL Trial No ClinicalTrials.gov ID |
Principal Investigator
Coordinator |
||
---|---|---|---|
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BRUIN-CLL-314 NCT05254743 Recruiting |
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS |
Chronic Lymphocytic Leukemia |
Dr. Robert Delage Philippe Nadeau 418-649-0252 poste 63115 |
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
BGB-11417-301 NCT06073821 Recruiting |
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT |
Chronic Lymphocytic Leukemia |
Dr. Dominique Toupin Anick Champoux 819-346-1110 poste 12811 |
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BRUIN CLL-322 NCT04965493 Recruiting |
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS |
Chronic Lymphocytic Leukemia |
Dr. Sonia Skamene Edrian Gabrielle Bumanlag 514-840-8222 poste 23638 |
A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies
MK-2140-006 NCT05458297 Recruiting |
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS |
Chronic Lymphocytic Leukemia Non-Hodgkin's Lymphoma |
Dr. Sarit Assouline Edrian Gabrielle Bumanlag 514-840-8222 poste 23638 |
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies
MK-1026-003 NCT04728893 Recruiting |
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX |
Chronic Lymphocytic Leukemia Non-Hodgkin's Lymphoma |
Dr. Isabelle Fleury Nawel Mechtouf 514-252-3400 poste 4681 |
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy
MK-1026-010 (BELLWAVE-010) NCT05947851 Recruiting |
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT |
Chronic Lymphocytic Leukemia |
Dr. Dominique Toupin Christine Lawson 819-346-1110 poste 12942 |
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
BGB-11417-301 NCT06073821 Recruiting |
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS |
Chronic Lymphocytic Leukemia |
Dr. Jean-François Larouche Philippe Nadeau 418-649-0252 poste 63115 |
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
BGB-11417-301 NCT06073821 Recruiting |
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE |
Chronic Lymphocytic Leukemia |
Dr. Mélina Boutin Fanny Raquepas Trudel 450-466-5000 poste 3593 |